Mogamulizumab, a monoclonal antibody directed against C-C-chemokine receptor 4 (CCR4) expressed on malignant and regulatory T-cells in the skin and peripheral blood, is approved for the treatment of MF and SS [9,10]. This evidence concerns the gene CCR4 and mycosis fungoides.